As the first study to observe BIRC5 knockout in the HepG2 cell line using the powerful CRISPR-Cas9 technology to target BIRC5 specifically and assess the effects of its deletion in HepG2 cell lines we examined at how BIRC5 affected migration, apoptosis, cell proliferation, and cell cycle dynamic and our results indicate that targeting BIRC5 via CRISPR-Cas9 represents a potential clinical technique in HCC with the potential to open the door for more powerful anticancer therapies. Here, BIRC5 is linked to hepatocellular carcinoma.